Study S000574

A PET/CT Study to Assess the Receptor Occupancy by SAR425899 After Repeat Dosing Using Radiolabelled Tracers for the Glucagon and GLP-1 Receptor in Overweight to Obese T2DM Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03350191
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 13
Start: 2017-12-20
Primary completion: 2018-06-07
Lead sponsor: Sanofi
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:SAR425899; DRUG:[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer); DRUG:[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:2017-001789-23; NIH:2017

Registered primary outcomes

Glucagon receptor occupancy [Day 1 and Day 20]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0053528	Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes Olof Eriksson, Journal of Nuclear Medicine	2021	Other	PMID 34503957 DOI	cites ClinicalTrials.gov:NCT03350191; registry reference DERIVED:34503957